PGNY Stock Analysis
PG
Neutral
Based on Eyestock quantitative analysis, PGNY`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Progyny, Inc. is a fertility benefits management company. The company is headquartered in New York City, New York and currently employs 393 full-time employees. The company went IPO on 2019-10-25. The firm specializes in fertility and family-building benefits solutions in the United States. The firm provides its benefit through its Smart Cycle approach. The Smart Cycles include medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition, to its fertility benefits solution, it offers an integrated pharmacy benefits solution, Progyny Rx, which is added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. As part of this solution, the Company provides care management services, which include its formulary plan design, simplified authorization, assistance with prescription fulfillment and timely delivery of the medications by its network of specialty pharmacies, as well as medication administration training, pharmacy support services and patient care advocates.